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Abstract
Background: Fibroblast-like synovial cells (FLS) have multilineage differentiation potential including osteoblasts. We
aimed to investigate the role of microRNAs during the osteogenic differentiation of rheumatoid arthritis (RA)-FLS.
Methods: RA-FLS were differentiated in osteogenic medium for 21 days. Osteogenic differentiation was evaluated
by alkaline phosphatase (ALP) staining and Alizarin Red staining. MicroRNA (miRNA) array analysis was performed to
investigate the differentially expressed miRNAs during osteogenic differentiation. Expression of miR-218-5p (miR-
218) during the osteogenic differentiation was determined by quantitative real-time PCR. Transfections with an miR-
218 precursor and inhibitor were used to confirm the targets of miR-218 and to analyze the ability of miR-218 to
induce osteogenic differentiation. Secreted Dickkopf-1 (DKK1) from FLS transfected with miR-218 precursor/inhibitor
or roundabout 1 (ROBO1) knockdown FLS established using ROBO1-small interfering RNA (siRNA) were measured
by ELISA.
Results: The miRNA array revealed that 12 miRNAs were upregulated and 24 miRNAs were downregulated after
osteogenic differentiation. We observed that the level of miR-218 rose in the early phase of osteogenic differentiation
and then decreased. Pro-inflammatory cytokines modified the expression of miR-218. The induction of miR-218 in RA-
FLS decreased ROBO1 expression, and promoted osteogenic differentiation. Both the overexpression of miR-218 and
the knockdown of ROBO1 in RA-FLS decreased DKK1 secretion.
Conclusion: We identified miR-218 as a crucial inducer of the osteogenic differentiation of RA-FLS. MiR-218 modulates
the osteogenic differentiation of RA-FLS through the ROBO1/DKK-1 axis. The induction of the osteogenic differentiation
of proliferating RA-FLS through the provision of miR-218 into RA-FLS or by boosting the cellular reservoir of miR-218
might thus become a therapeutic strategy for RA.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease characterized by marked hyperplasia of the lining layer
of the synovium, leading to the destruction of articular
cartilage and bone. In RA pathogenesis, fibroblast-like
synovial cells (FLS) are pivotal. FLS contribute to the pro-
duction of pro-inflammatory cytokines, small molecule
mediators of inflammation, and proteolytic enzymes that
degrade the extracellular matrix [1]. Moreover, FLSs are
resistant to programmed cell death [2], resulting in an
aggressive, invasive phenotype similar to that of an invasive
cancer, and the hyperplastic synovial tissue, also called the
pannus, destroys cartilage and bone. Although rapid devel-
opment of cytokine-targeted therapeutic agents such as
tumor necrosis factor (TNF) inhibitors has provided better
clinical outcomes including achievement of remission for
patients with RA, there are many unfavorable problems
such as inadequate response, high cost, and adverse events
such as infections [3, 4]. RA-FLS-targeted therapies have
thus been explored, and several key mediators that activate
cytokine production from FLS [5, 6] or acquire
anti-apoptosis property [7] had been elucidated. However,
despite the enthusiasm for developing new treatments that
directly target FLS, no directly FLS-targeted therapy is
available at this time.
In RA, FLS of mesenchymal origin conserve mesenchymal
properties. The gene expression pattern of FLS is similar to
that of mesenchymal stem cells [8], and in vitro studies have
shown that appropriate stimulation in culture induces differ-
entiation of FLS into chondrocytes, adipocytes, muscle cells,
and osteoblasts [9–11]. FLS are bone marrow (BM)-derived
mesenchymal cells (MSCs) [12], and the multi-linage poten-
tial of arthritic FLS is thought to be arrested at the early
stage of differentiation by activation of nuclear factor-κB
(NF-κB) [13]. Forced cell differentiation might become a
candidate therapeutic option for RA; for example, mesen-
chymal stromal cells showed reduced interleukin-6 (IL-6)
production after their differentiation into adipocytes [14].
Until now, there has been no evidence that FLS differentiate
into osteoblasts in joints. However, if the induction of intrin-
sic transdifferentiation of markedly proliferating FLS in the
joints causes differentiation of FLS into osteoblasts, it might
become a treatment option for RA.
MicroRNAs (miRNAs) are small non-coding RNAs,
which regulate gene expression post-transcriptionally
by binding to the 5′ untranslated region (UTR), coding
regions or 3′ UTR of mRNA [15]. Altered expression of
miRNAs has been reported in many diseases such as
cancer, infections, and autoimmune diseases including
RA, and this might arise from a modulation of diverse
biological processes such as cell proliferation, apop-
tosis, metabolism and cell differentiation by miRNAs
[16–18]. There is growing evidence that miRNAs are
critical in osteoblast differentiation [19].
Jie et al. reported that miR-145 suppressed the osteo-
genic differentiation of mouse osteoblastic and myoblas-
tic cell lines (MC3T3 and C2C12) by targeting Sp7 [20].
Other reports revealed that several miRs, e.g., miR-
218, miR-34 and miR-195 modulate osteogenic differ-
entiation by suppressing their targets [21–23]. How-
ever, the effect of miRNAs on RA-FLS differentiation
including osteoblast differentiation had not yet been
elucidated.
In the present study, we identified a miRNA (miR-218)
that was altered during the osteogenic differentiation of
RA-FLS, and we confirmed that this miRNA indeed pro-
moted the osteogenic differentiation of RA-FLS. Our
findings also revealed that Wnt/β-catenin signaling is in-
volved in the promotion of the osteogenesis of RA-FLS
by miR-218.
Methods
Isolation of FLS and stimulation assays
We obtained synovial tissues from patients with RA who
fulfilled the 2010 American College of Rheumatology
(ACR)/European League Against Rheumatism (EULAR)
classification criteria for RA [24] or the 1987 ACR classifi-
cation criteria for RA [25] at the time of orthopedic sur-
gery. Each patient provided a signed consent form to
participate in the study, which was approved by the Insti-
tutional Review Board of Nagasaki University and the
Swiss Ethical commission. FLS were isolated from synovial
tissues as described previously [26, 27]. Cells were culti-
vated in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% heat-inactivated fetal bovine serum (FBS),
100 units/ml penicillin and 100 ng/ml streptomycin (all
from Gibco, Basel, Switzerland). FLS from passages 3–8 in
monolayer culture were used for the experiments. In the
stimulation experiments, FLS were stimulated for 24 h
with recombinant TNF-α (10 ng/ml), interleukin-1β
(IL-1β) (1 ng/ml) (R&D Systems, Abingdon, UK), recom-
binant interleukin-6 (IL-6) (100 ng/ml) and recombinant
soluble IL-6 receptor (sIL-6R) (100 ng/ml) (Peprotech,
Rocky Hill, NJ, USA).
Osteogenic differentiation in vitro
RA-FLSs were plated at a cell density of 1 × 104 in
12-well plates. After they were 70% confluent, medium
was replaced with osteogenic differentiation Bulletkit™
medium containing dexamethasone, ascorbate, glycero-
phosphate, L-Glutamine, Pen/Strep and MCGS (Lonza,
Walkersville, MD, USA) to differentiate to osteoblasts.
RA-FLS was cultured in the induction medium for up to
21 days. The medium was changed every 3 days. Osteo-
blast differentiation was evaluated by alkaline phosphat-
ase (ALP) staining and Alizarin Red staining.
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ALP staining and Alizarin Red staining
After the osteogenic induction or transfection experi-
ments, cells were fixed in 4% paraformaldehyde and
stained with ALP using ALP staining kit (Cosmo Bio,
Tokyo). In another set of experiments, we performed
Alizarin Red staining to detect the calcification after
21 days of culture in induction medium (late period of
induction). Cells were fixed in methanol and stained
with Alizarin Red using Calcified Nodule Staining kit
(Cosmo Bio). ALP-positive cells were stained blue by
ALP staining, and calcium nodules were detected as red
bodies by Alizarin Red staining.
Transfection experiments
For a transient transfection approach with the aim to in-
hibit or enhance the miR-218 function, RA-FLSs were
transfected with synthetic precursor miRNA (Pre-miR),
with inhibitors of miR-218 (anti-miR), or with scrambled
controls (Pre-miR/Anti-miR Negative Control #1;
Ambion/Applied Biosystems, Foster City, CA, USA) at a
final concentration of 100 nM with the use of Lipofecta-
mine 2000 reagent (Invitrogen, Carlsbad, CA, USA). In
another set of experiments, RA-FLSs were transfected
with specific small interfering RNA (siRNA) that target
ROBO1 mRNA using FlexiTube siRNA Premix (Qiagen,
Hilden, Germany) at a final concentration of 25 nM ac-
cording to the manufacturer’s protocol. AllStars Nega-
tive control siRNA (siRNA-premix, Qiagen) served as a
control. Transfection efficiency of pre/anti-mir-218 and
siRNA were controlled by TaqMan-based real-time poly-
merase chain reaction (PCR).
RNA isolation and quantitative real-time PCR analysis
A mirVana miRNA Isolation kit was used for isolation of
total RNA (Ambion/Applied Biosystems). Specific single
TaqMan miRNA assays (Ambion/Applied Biosystems)
were used to measure the expression levels of selected
miRNA in a model light cycler 1.5 (Roche Diagnostics).
Expression of the U6B small nuclear RNA (RNU6B) was
used as endogenous control to normalize the data. In
the analysis of the expression of specific mRNA, gene
expression was quantified using SYBR Green Real-time
PCR, as previously described [27]. The primers were ob-
tained from Takara Bio (Tokyo) and Integrated DNA
Technologies (Coraville, IA, USA). The primer se-
quences are shown in Table 1. The amounts of loaded
complementary DNA (cDNA) were normalized using
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as
an endogenous control. For relative quantification, the
comparative threshold cycle (Ct) method was used.
In silico prediction analysis of miRNA targeting genes
MiRecords (http://c1.accurascience.com/miRecords/) was
used to predict miRNA transcript targets. MiRecords is a
database that combines the following miRNA target pre-
diction tools: DIANA-microT, Micro inspector, miRanda,
Mir Target2, mi Target, NB miRTar, Pic Tar, PITA, RNA
hybrid, and TargetScan. Results were filtered based on the
observation that a given miRNA targeted a transcript
present in a minimum of five of these miRNA target pre-
diction tools.
ELISA
Protein in cell supernatant was detected by ELISA with an
ELISA kit specific for Dickkopf-1 (DKK1) according to
the manufacturer’s instructions (R&D Systems). Absorp-
tion was measured at 450 nm.
miRNA and DNA microarray assay analyses
miRNA expression profiles during osteogenic differenti-
ation were established by applying SurePrint G3 Human
miRNA, 8 × 60 K (release 18.0) microarrays containing
1887 human miRNA oligonucleotide probes (Agilent
Technologies, Santa Clara, CA, USA). DNA microarray
analysis was performed using whole human genome
DNA microarray SurePrint G3 Human Gene Expression,
8 × 60 K (ver. 2) microarrays (Agilent Technologies). All
procedures were carried out according to the manufac-
turer’s recommendations. Microarray data were analyzed
by GeneSpring software ver. 12.5.0 or 12.6.1 (Agilent
Technologies). The raw signals were log2 transformed
and normalized using the percentile shift normalization
method: the value was set at the 90th percentile for
miRNA microarray and the 75th percentile for DNA
microarray.
Table 1 SYBR green primers used for real-time PCR
ALP forward 5′-AGCTCAACACCAACGTGGCTAA-3′
ALP reverse 5′-TTGTCCATCTCCAGCCTGGTC-3′
RUNX2 forward 5′-CTTTGTAGCACAAACATTGCTGGA-3′
RUNX2 reverse 5′-AAAGCTGTGGTACCTGTTCTGGA-3′
CTNNB1 forward 5′-CATCCTAGCTCGGGATGTTCAC-3′
CTNNB1 reverse 5′-TCCTTGTCCTGAGCAAGTTCAC-3′
CDH11 forward 5′-CAGGTGCTACAGCGCTCCAA-3′
CDH11 reverse 5′-TTAATGTTCCCATCACCAGAGTCAA-3′
ROBO1 forward 5′-CGGCAGAGTATGCTGGTCTGAA-3′
ROBO1 reverse 5′-CTAGGGCACTGAGACGCATGAA-3′
DKK1 forward 5′-CCAGACCATTGACAACTACCAG-3′
DKK1 reverse 5′-AGGCGAGACAGATTTGCAC-3′
GAPDH forward 5′-GCACCGTCAAGGCTGAGAAC-3′
GAPDH reverse 5′-TGGTGAAGACGCCAGTGGA-3′
CDH11 cadherin 11, ALP alkaline phosphatase, RUNX2 runt related transcription
factor 2, CTNNB catenin beta 1, ROBO1 roundabout 1, DKK1 dickkopf-1, GAPDH
glyceraldehyde-3-phosphate dehydrogenase
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Statistical analyses
GraphPad Prism software (GraphPad, San Diego, CA,
USA) was used for statistical analyses. Normal distribu-
tions of the data were confirmed using the Kolmogorov-
Smirnov test. Statistical significance was evaluated by Stu-
dent’s paired t test (for parametric data) or the Wilcoxon
matched-pairs signed rank test (non-parametric data) for
related data. All data are expressed as the mean ± standard
error of the mean (SEM). p values < 0.05 were considered
significant.
Results
RA-FLS osteogenic differentiation
We first investigated whether RA-FLS can differentiate
into osteoblasts. To induce the differentiation of RA-
FLS, the medium was replaced with osteogenic induc-
tion medium. Osteoblasts were then evidenced by ALP
staining (Fig. 1a, b) and Alizarin Red staining for matrix
mineralization (Fig. 1a, c). ALP and runt related tran-
scription factor 2 (RUNX2) were used as phenotypic
markers of osteogenic differentiation, and as shown in
Fig. 1d, the expression of those mRNAs was significantly
increased at day 21 after osteogenic induction.
Expression of miR-218 during osteogenic differentiation
of RA-FLS
To explore miRNAs involved in the osteogenic differen-
tiation of RA-FLS, we started by examining the miRNA
expression profiles by microarrays. Our microarray
analysis of three pairs (RA-FLS cultured in osteogenic
induction medium versus an untreated control) identi-
fied 36 differentially expressed miRNAs among all three
pairs. Of these, 12 miRNAs were upregulated miRNA s
and 24 were downregulated miRNAs (Additional file 1:
Figure S1).
Among these miRNAs, miR-218-5p (miR-218) was one
of the most significantly and consistently downregulated
miRNAs after osteogenic induction. To validate the micro-
array findings, quantitative real-time PCR with additional
RA-FLS cultured in osteogenic induction medium was per-
formed. In agreement with the microarray analysis results,
there was significant downregulation in the expression of
Fig. 1 Osteogenic differentiation of rheumatoid arthritis (RA)-fibroblast-like synovial cells (FLS) cultured in osteogenic induction medium. a Representative
images of alkaline phosphatase (ALP) staining (right) and Alizarin Red staining (left). RA-FLS (n= 6) were cultured in osteogenic induction medium or control
medium. After 21 days, cells were stained with ALP and Alizarin Red. b Representative image of the morphology of RA-FLS with ALP staining. Right: RA-FLS
were cultured in control medium. Left: RA-FLS were cultured in osteogenic induction medium (magnification × 200). c Visualization of calcified nodules by
Alizarin Red staining. RA-FLS were cultured in osteogenic induction medium (magnification × 400). d RA-FLS (n= 5) were cultured in osteogenic induction
medium or control medium for 21 days. Expression of ALP, runt related transcription factor 2 (RUNX2) was determined by quantitative real-time PCR.
Values are presented as means ± SEM: *p < 0.05 versus control, as determined by Student’s paired t test or Wilcoxon matched-pairs signed rank test
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mir-218 after osteogenic induction. The miR-218 decreased
with fold-change of 0.203 ± 0.026 (p < 0.0001) at day 21
after osteogenic induction compared with the untreated
control (Fig. 2a). We next investigated the time course of
miR-218 expression during osteogenic differentiation. In
response to osteogenic differentiation, miR-218 rose until
12 h and then decreased at 7 days, and remained decreased
at 21 days (Fig. 2b).
miR-218 promotes osteogenesis of RA-FLS
To determine the role of miR-218 in the osteogenic dif-
ferentiation of RA-FLS, RA-FLS were transfected with
pre-miR-218 or anti-miR-218 and the respective negative
control. In RA-FLS, transfection with pre-miR-218
increased the levels of miR-218 with fold-change of 1.34
× 105 ± 1.70 × 105 compared to the scrambled control.
Knockdown with anti-miR-218 reduced the expression
of miR-218 with fold-change of 0.098 ± 0.058 indicating
successful transfection. At 14 days after transfection,
osteogenesis ability was examined. Strong ALP staining
was observed (Fig. 3a, b). Interestingly, in addition to
ALP and RUNX2 mRNA, other osteogenesis-associated
genes such as catenin beta 1 (CTNNB1) and cadherin 11
(CDH11) were also significantly upregulated in pre-miR-
218 transfected RA-FLS compared to the scrambled
control from 72 h after transfection (Fig. 3c). In contrast,
in the anti-miR-218 transfected RA-FLS, no ALP stain-
ing was observed (Fig. 3a), and osteogenic specific
markers were not upregulated. Moreover, the transfec-
tion of anti-miR-218 did not attenuate the osteogenic
differentiation induced by osteogenic induction medium
(please contact author for data requests). This gain-
and-loss of function assays with miR-218 showed
miR-218 solely induced the osteogenic differentiation of
RA-FLS without osteogenic induction medium.
The expression of miR-218 is modulated by pro-
inflammatory cytokines
We next investigated whether miR-218 is modulated in
the physiopathological condition of RA. To simulate the
inflammatory conditions present in RA in vivo, we stimu-
lated RA-FLS with TNF-α and IL-1β or IL-6. Although
the difference was not statistically significant, the stimula-
tion of these cytokines downregulated the expression of
miR-218 numerically (Additional file 2: Figure S2). This
result suggests that the conditions in which inflammation
occurs in RA, which is a bone erosion-progressive state,
also presents a disadvantage for the osteogenic differenti-
ation of RA-FLS.
ROBO1 is targeted by miR-218 in RA-FLS
To elucidate the functional consequences of upregula-
tion of miR-218, we searched for potential gene targets
of miR-218 that might contribute to the osteogenesis of
RA-FLS. We performed a DNA microarray using
gain-and-loss of function assays with miR-218, and we
also conducted an in silico identification of potential
gene targets of miR-218 using the MiRecords (http://
c1.accurascience.com/miRecords/). From the microarray
result, the genes increased by knockdown of miR-218
and decreased by overexpression of miR-218 were con-
sidered as potential targets (microarray data are available
from Gene Expression Omnibus (GEO, http://
www.ncbi.nlm.nih.gov/geo/) [GEO:GSE 111946]. Among
the candidates that were predicted by both in silico and
microarray analyses, we focused on roundabout 1
(ROBO1), a transmembrane receptor proteins implicated
in the Slit-ROBO pathway with an established relation-
ship to osteogenesis [28], and we further analyzed
ROBO1. Overexpression of miR-218 reduced the expres-
sion of ROBO1 with fold-change of 0.29 ± 0.07 (p < 0.05)
Fig. 2 Expression of microRNA-218-5p (miR-218) during osteogenic differentiation of rheumatoid arthritis (RA)-fibroblast-like synovial cells (FLS), as
determined by TaqMan-based Real-time polymerase chain reaction analysis. Expression of miR-218 in osteogenic differentiation was determined
relative to the controls, which was defined as 1. a miR-218 was markedly reduced in RA-FLS (n = 5) at 21 days after culture in osteogenic induction
medium compared to culture in control medium. Values are presented as means ± SEM: *p < 0.0001 versus control, as determined by Student’s paired
t test. b The time course of expression of miR-218 during osteogenic differentiation (n = 4–5). Points and bars represent means and SEM respectively:
*p < 0.05 versus control, as determined by Student’s paired t test
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at the mRNA level. Conversely, knockdown of miR-218
increased the expression of ROBO1 with fold-change of
1.34 ± 0.10 (p < 0.05) (Fig. 4a, b). Taken together, these
findings confirmed ROBO1 as a target of miR-218 in
RA-FLS.
miR-218 and the suppression of ROBO1 promote
osteogenesis through DKK1 suppression
Wnt/β-catenin signaling plays a crucial role in osteogen-
esis [29], therefore we next investigated whether miR-218
affects inhibitor of Wnt/β-catenin signaling. The level of
Fig. 3 Overexpression of microRNA-218-5p (miR-218) promotes osteogenic differentiation of rheumatoid arthritis (RA)-fibroblast-like synovial cells (FLS).
a Alkaline phosphatase (ALP) staining at day 14 showed the enhanced ALP activity of osteogenic differentiation after transfection with precursor miR-
218 (pre-miR-218) compared to scrambled RNA-transfected controls. Images are representative of five samples. b The morphology of RA-FLS with ALP
staining. Right: RA-FLS were transfected with scrambled control. Left: RA-FLS were transfected with pre-miR-218 (magnification × 200). Images are
representative of five samples. c Transfection of RA-FLS (n = 5) with pre-miR-218 for 72 h compared with scrambled RNA transfected controls increased
the level of ALP, runt related transcription factor 2 (RUNX2), catenin beta 1 (CTNNB1), cadherin 11 (CDH11) as determined by quantitative real-time PCR
analysis. Values are presented as means ± SEM: *p < 0.05 versus scrambled RNA-transfected controls, as determined by Student’s paired t test
Fig. 4 Influence of overexpression and knockdown of microRNA-218-5p (miR-218) on the expression of roundabout1 (ROBO1). Expression of
ROBO1 in rheumatoid arthritis (RA)-fibroblast-like synovial cells (FLS) was determined relative to the controls transfected with scrambled RNA,
which was defined as 1. a Transfection of RA-FLS (n = 5) with precursor miR-218 (pre-miR-218) for 48 h decreased the levels of ROBO1 compared
to scrambled RNA-transfected controls, as determined by SYBR green real-time PCR analysis. b Knockdown of miR-218 for 48 h in RA-FLS (n = 5)
increased the level of ROBO1 compared to scrambled RNA-transfected controls, as determined by SYBR green real-time PCR analysis. Values are
presented as means ± SEM: *p < 0.05 versus scrambled RNA-transfected controls, as determined by Student’s paired t test
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DKK1 (which has been shown to be a potent inhibitor of
Wnt/β-catenin signaling) that we detected in RA-FLS
transfected with pre-miR-218-conditioned medium was
significantly reduced compared to that detected in scram-
bled control-conditioned medium (Fig. 5a). These findings
were confirmed at the mRNA level by quantitative real-
time PCR. Overexpression of miR-218 reduced the
expression of DKK-1 with fold-change of 0.33 ± 0.08
(p < 0.005) (Fig. 5b).
To mimic the promotion of the osteogenic condition
of RA-FLS by miR-218 as we observed, we silenced the
expression of ROBO1 with siRNA. After transfection
with ROBO1-specific siRNA, the expression of ROBO1
was decreased with fold-change of 0.30 ± 0.08, indicating
successful transfection. Similar to the effect of miR-218
overexpression, silencing of ROBO1 reduced DKK1 se-
cretion from RA-FLS (Fig. 5c). These results suggest that
miR-218 promote osteogenic differentiation of RA-FLS
through ROBO1 suppression and inhibition of DKK1 se-
cretion, therefore activation of Wnt/β-catenin signaling
is presumed to be the possible mechanism of miR-218-
induced osteogenesis of RA-FLS.
Discussion
This is the first study to show that a miRNA could induce
the osteogenic differentiation of FLS from RA, a bone-ero-
sive disease. Our findings demonstrated that the
expression of miR-218 was altered during osteogenic in-
duction and most interestingly, miR-218 directly pro-
moted the osteogenic differentiation of RA-FLS through
the suppression of DKK1.
Skeletal homeostasis is a continuous process that is
maintained by a balance between bone resorption by
osteoclasts and bone formation by osteoblasts. In RA,
bone erosion is considered to be the result of a disrup-
tion of this balance, inadequate bone formation, and an
enhancement of osteoclast activity [30]. Inadequate bone
formation in RA was recently elucidated. Two studies
reported that IL-6, a key pro-inflammatory cytokine of
RA, decreased osteoblast proliferation and induced
osteoblast apoptosis [31, 32]. IL-6 inhibited the forma-
tion of mineralized bone nodules in an in vitro rat osteo-
genesis model [32]. Another study focused on DKK1,
which we observed to be a key regulator of the promo-
tion of osteogenesis by miR-218. DKK1 expression was
Fig. 5 Suppression of Dickkopf-1 (DKK1) by overexpression of microRNA-218-5p (miR-218) or silencing of roundabout1 (ROBO1). a At the protein level,
transfection of rheumatoid arthritis (RA)-fibroblast-like synovial cells (FLS) (n = 4) with precursor miR-218 (pre-miR-218) for 48 h decreased DKK1 protein
production in the culture supernatant compared to scrambled RNA transfected controls, as determined by ELISA. Graphs represent optical density
(OD) value; each mean amount of DDK1 protein are as follows; scrambled control: pre-miR-218 1.17 ng/ml:0.76 ng/ml, scrambled control: anti-miR-218
1.58 ng/ml:1.65 ng/ml, respectively. b At the mRNA level, transfection of RA-FLS (n = 4) with pre-miR-218 for 48 h decreased DKK1 expression
compared to scrambled RNA transfected controls, as determined by SYBR green real-time PCR analysis. c Secretion of DKK1 from RA-FLS (n = 4) was
decreased after transfection with ROBO1-specific small interfering RNA (siRNA) compared to the scrambled RNA transfected controls, as determined by
ELISA. Graphs represent OD value; each mean amount of DDK1 protein are as follows; scrambled control: siROBO1.28 ng/ml:1.09 ng/ml, respectively.
Values are presented as means ± SEM: *p < 0.05 versus scrambled RNA-transfected controls, as determined by Student’s paired t test
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increased in FLS and endothelial cells in an animal
model of arthritis, and TNF markedly increased the pro-
duction of DKK1 from cultured FLS. In addition, serum
DKK1 was elevated in patients with RA [33].
An in vivo study by Walsh et al. using an animal
model of RA demonstrated that the presence of inflam-
mation modified osteoblast-lineage cell function, result-
ing in impaired osteoblast maturation and significant
reduction of mineralized bone formation within the site
of arthritic erosion [34]. In clinical practice, the repair
of bone erosion is uncommon but it has been demon-
strated to occur. For example, 6% of patients with RA
treated with adalimumab were shown to have bone re-
pair [35], and 1-year treatment with TNF inhibitor was
shown to reduce the mean depth of erosion detected by
high-resolution computed tomography [36]. Although
the mechanisms underlying the repair of bone erosion
in RA have been not elucidated, the possible main
mechanism might be the correction of the imbalance of
bone remodeling that arises from inflammation. It is
not elucidated that the osteogenic differentiation of
RA-FLS, which we showed in an in vitro study, occurs
in the joints in RA. However, if it does occur in the
joints in RA, it is possible that proliferation of FLS con-
tributes to bone repair by induction of osteogenic dif-
ferentiation by miR-218.
Although the role of miR-218 in human disease and
cell physiology has not been widely addressed, several
studies of miR-218 have been reported. For example,
miR-218 suppresses gastric cancer cell proliferation via
regulation of angiopoietin-2 [37], and miR-218 inhibits
proliferation of glioma cells by targeting ROBO1 [38].
Two studies revealed that miR-218 promotes osteogenic
differentiation of mesenchymal stem cells through regu-
lation of Wnt/β-catenin signaling, targeting DKK2, scler-
ostin, and secreted frizzled related protein 2 [22, 39].
The difference in targets compared to our present study
might be due to the difference in the types of cells exam-
ined, because miRNA may have different effects depend-
ing on cell type.
Our study suggests that the ROBO1-DKK1 axis is im-
portant for osteogenesis in RA-FLS. ROBO1 is a member
of the ROBO family; it serves as a transmembrane recep-
tor of Slit, and emerging evidence has indicated that a
ROBO/Slit signaling pathway is crucial in axon guidance
[40]. In addition to axon guidance, the ROBO/Slit path-
way is also involved in cell processes such as cell prolifera-
tion, cell motility, and angiogenesis [41, 42]. The effect of
the ROBO/Slit signaling pathway in osteogenesis remains
unknown, but Sun et al. reported that slit2 reduced ALP
expression and osteoblastic gene expression in the osteo-
blastic cell line MC3T3-E1 [28]. Our present findings also
showed that knockdown of ROBO1 significantly reduced
DKK1 secretion from RA-FLS.
Wnt/β-catenin signaling is known as one of the im-
portant molecular cascades and is central to osteogen-
esis, and DKK1 is a potent inhibitor of this signaling
pathway, causing deregulation of bone formation [43].
As described above, in vivo and in vitro studies have
shown an increase of DKK1 in both an arthritic animal
model and in patients with RA. In fact, patients with RA
with radiological progression within 2 years have been
shown to have higher baseline levels of serum DKK1
compared to the patients without radiological progres-
sion [44]. Wang et al. reported that serum DKK1 is
significantly correlated with bone erosion, and that treat-
ment with a TNF-α inhibitor or IL-1 receptor antagonist
decreased serum DKK1 levels [45]. Considering these
results, the reduction of DKK1 secretion by miR-218
might provide a protective effect against RA bone
erosion besides the effect of miR218 toward RA-FLS
osteogenesis.
In the present study, miR-218 promoted osteogenic
differentiation despite a significant decrement of miR-
218 after osteoblast differentiation. A negative and posi-
tive feedback loop between microRNA and its target
gene or cellular response have been observed [46–48].
This crosstalk was also seen in the Wnt/β-catenin
signaling pathway; miR-122 inhibits the Wnt/β-catenin
signaling pathway, which negatively regulates the expres-
sion of miR-121 in glioma cells [49]. miR-372 and
miR-373 activate the Wnt/β-catenin signaling pathway
by targeting Wnt/β-catenin signaling inhibitors includ-
ing DKK1, and these miRs are induced by Wnt/β-ca-
tenin signaling-dependent transcription [50]. Such
crosstalk with miR-218 might be implicated in RA-FLS
osteogenesis.
Conclusions
In conclusion, our study showed that the expression of
miR-218 was altered during the osteogenic differenti-
ation of RA-FLS, and that miR-218 promoted the osteo-
genic differentiation of RA-FLS by targeting ROBO1 and
suppressing DKK1. The induction of the osteogenic
differentiation of proliferated FLS in RA synovial tissue
has two potential effects; the attenuation of RA disease
progression derived from FLS as effector cells, and the
repair of destruction of bone. Therefore, strategies to
provide miR-218 to RA-FLS or to boost the cellular res-
ervoir of miR-218 might become a therapeutic strategy
for RA. This attractive hypothesis should be further
tested in animal models. At the least, overexpression of
miR-218 might contribute to bone repair and suppres-
sion of bone erosion by the inhibition of DKK1 secre-
tion, which we observed herein as an effect of miR-218
in RA-FLS, and modification of the inflammatory and
invasive phenotype of RA-FLS.
Iwamoto et al. Arthritis Research & Therapy  (2018) 20:189 Page 8 of 10
Additional files
Additional file 1: Figure S1. Alteration of miRNA expression after
osteogenic induction as shown by microarray analysis. (A) There are 24
microRNAs in the downregulated group. (B) There are 12 microRNAs in
the upregulated group. Values are given as means of three pairs
(cultured in osteogenic induction medium vs in control medium). We
defined “altered miRNA” that were upregulated or downregulated in all
three pairs. (TIF 1935 kb)
Additional file 2: Figure S2. Pro-inflammatory cytokines modulated the
expression of microRNA-218 (miR-218). RA-FLS (n = 4–6) were stimulated
with recombinant tumor necrosis factor-α (TNF-α) (10 ng/ml) and
interleukin-1β (IL-1 β) (1 ng/ml) or interleukin 6 (IL-6) (100 ng/ml) with sol-
uble IL-6 receptor (sIL-6R) (100 ng/ml) for 24 h to explore the effects on
miR-218 expression. Expression of miR-218 determined by TaqMan-based
real-time polymerase chain reaction was expressed relative to the control,
which was defined as 1. Values are presented as means ± SEM. (TIF 299 kb)
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